Glycostem is delighted that we have been listed as the only not-public listed company in this article. If you are interested in the NK cell space, this is a recommended read.
April 20, 2016
On the 20th of April 2016, the FDA Office of Orphan Products Development has granted orphan drug designation to Glycostem's NK Cell Product oNKord® for treatment of acute myeloid leukemia (AML)
New home for Glycostem's R&DRead more >
On the 2nd December Glycostem has officially launched its new website, which provides a comprehensive overview of our current position and ambitious plans on the application of NK cell immunotherapy in the treatment of cancer.Read more >
ODD for NK Cell Product oNKord® to treat AMLRead more >